Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until ...

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment ...

Credit: Getty Images Study reveals factors that could distinguish PSA bounce from biochemical recurrence after stereotactic body radiation therapy for prostate cancer. Investigators have identified ...

Share on Pinterest UCLA researchers recently found that PSA levels after prostate cancer treatment may not be the best indicator of survival. andresr/Getty Images A new study from UCLA researchers ...

A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Treatments intended to reduce biochemical recurrence in patients with prostate cancer may not improve long-term survival, recent research showed. Certain prostate cancer treatments used to reduce the ...

Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.

− Post-hoc analysis from Blue Earth Diagnostics’ Phase 3 SPOTLIGHT trial provides data about treatment planning, particularly when curative salvage therapy is considered – MONROE TOWNSHIP, N.J. & ...

A Purdue University mechanical engineer and his international collaborators have developed a patent-pending method and algorithm to predict the recurrence of prostate cancer in patients treated by ...